$SRPT,,This stock is on the BioPharma Update which I sent along yesterday. In after hours, this stock shot up $5.67 to $39.75. As I believe when news like this comes out, it will take the indicators a few days to shake out what is happening and where this is headed. Right now UP. My plan is to wait to see what happens after the bell and hopefully take out some who want to cash in on profits. I plan to get in on any dips this might have (if any).


Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are trading up 14% in the after-hours session to $38.70 following better than expected sales data reported in its 2Q earnings release. Sales from Exondys 51, approved by the FDA in 2016 for the treatment of Duchenne muscular dystrophy, were $35m in 2Q 2017, above market estimates of around $22m. Guidance was also raised for 2017 to between $125m and $130m, above previous consensus of $105m.